Elevance Health Inc. (ELV) continues to attract positive attention from the investment community. Q2 2024 earnings have beaten estimates, sending a positive signal to investors and analysts. Despite spiking medical costs, ELV stock's projected price target is $604.29. However, Wells Fargo adjusted this to $593.00, while TD Cowen and Royal Bank of Canada set it at $589.00 and $585.00 respectively. Elevance is seeing steady growth with its dividends and share value, providing a good return for investors. Directors and the CEO are making significant insider sales. Despite pressure on Medicaid and lower valuations of peers leading to a downgrade by BofA, the company's stock performance attracts interest. In addition, Elevance is making strategic moves, notably the partnership with Clayton, Dubilier & Rice to advance primary care and the acquisition of CarelonRx via Paragon. The company is expected to maintain its annual guidance, after surpassing market expectations for Q2's profit and revenue. Regardless, concerns are raised about the company's debt management strategy.
Elevance Health ELV News Analytics from Wed, 24 Jan 2024 08:00:00 GMT to Sun, 28 Jul 2024 06:24:50 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor 4
